September 03, 2025 a 12:39 pm

TMO: Analysts Ratings - Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. Stock Analysis

Thermo Fisher Scientific Inc. (TMO), a leader in providing innovative solutions and services in the life sciences sector, continues to draw significant interest from analysts. The stock has shown resilience amidst market fluctuations, supported by its diversified business model. Analyst ratings reflect cautious optimism, though shifts in ratings indicate the potential for changing sentiment.

Historical Stock Grades

Analyzing the latest data reveals a balanced analyst sentiment toward Thermo Fisher Scientific, with predominant Buy ratings but noticeable Hold positions. Recent ratings illustrate consistent enthusiasm combined with pockets of circumspection.

Recommendation Number Score
Strong Buy 6
Buy 16
Hold 7
Sell 0
Strong Sell 0
Historical Analyst Ratings for TMO Stock Chart of TMO

Sentiment Development

The sentiment surrounding Thermo Fisher Scientific has seen slight adjustments in the past months. Notable is the gradual reduction in Strong Buy recommendations, transitioning into more Hold positions:

  • The overall number of analyst ratings has remained relatively stable, suggesting consistent interest from investors.
  • A decrease in Strong Buy ratings from 8 to 6 suggests a cautious shift among analysts.
  • Hold ratings have increased, indicating potential risk-aversion.

Percentage Trends

Percentage analysis illustrates a subtle but meaningful transition in analyst ratings, with incremental shifts away from bullish outlooks:

  • Strong Buy ratings were 25% last month, now at 20%, demonstrating reduced aggressive optimism.
  • Hold positions grew from approximately 26% to 23%, signifying a rise in moderate appraisal.
  • These changes suggest analysts are adopting a more conservative perspective on the stock’s short-term potential.
  • Over the past year, the buy sentiment has slightly decreased, while Hold ratings have increased, reflecting market caution.

Latest Analyst Recommendations

Recent analyst endorsements for Thermo Fisher present a picture of continuity, with no significant changes to previous positions:

Date New Recommendation Last Recommendation Publisher
2025-07-24 Outperform Outperform Baird
2025-07-24 Neutral Neutral UBS
2025-07-24 Equal Weight Equal Weight Barclays
2025-07-24 Overweight Overweight Wells Fargo
2025-07-24 Outperform Outperform Raymond James

Analyst Recommendations with Change of Opinion

Thermo Fisher’s recent recommendation changes highlight a slight shift toward more conservative outlooks. Notably, Scotiabank upgraded its rating while UBS and others opted for downgrades:

Date New Recommendation Last Recommendation Publisher
2025-07-11 Sector Outperform Sector Perform Scotiabank
2025-07-09 Neutral Buy UBS
2024-01-24 Equal Weight Overweight Barclays
2024-01-08 Market Perform Outperform Bernstein
2023-10-26 Sector Weight Overweight Keybanc

Interpretation

Thermo Fisher Scientific's market perception remains largely positive, though caution is evident. Analysts show mixed sentiments, balancing between optimism and prudence, reflecting on broader market conditions and sector-specific factors. The frequency and consistency of recommendations indicate robust interest, yet the gradual increase in Hold ratings suggests growing concerns or wait-and-see attitudes.

Conclusion

Thermo Fisher Scientific continues to maintain a favorable position in the market, supported by a steady flow of innovative products and services. While analyst ratings remain predominantly favorable, the rise in Hold recommendations points to caution amidst potential market volatility. Nevertheless, the company’s diversified portfolio and resilience offer substantial prospects. Investors should remain vigilant of macroeconomic trends and sector-specific developments when considering their positions in TMO. Overall, Thermo Fisher Scientific appears well-positioned but faces natural market challenges compounded by external pressures.